

Yu-Mi Wi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8916539/publications.pdf>

Version: 2024-02-01

41
papers

793
citations

516710

16
h-index

552781

26
g-index

41
all docs

41
docs citations

41
times ranked

1531
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding Biofilms and Novel Approaches to the Diagnosis, Prevention, and Treatment of Medical Device-Associated Infections. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 915-929.	5.1	61
2	Evaluation of the CosmosID Bioinformatics Platform for Prosthetic Joint-Associated Sonicate Fluid Shotgun Metagenomic Data Analysis. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	59
3	Microbiological features and clinical impact of the type VI secretion system (T6SS) in <i>Acinetobacter baumannii</i> isolates causing bacteremia. <i>Virulence</i> , 2017, 8, 1378-1389.	4.4	57
4	Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience. <i>Journal of Korean Medical Science</i> , 2021, 36, e107.	2.5	57
5	Viral kinetics of SARS-CoV-2 over the preclinical, clinical, and postclinical period. <i>International Journal of Infectious Diseases</i> , 2021, 102, 561-565.	3.3	46
6	Treatment of Extrapulmonary Nontuberculous Mycobacterial Diseases. <i>Infection and Chemotherapy</i> , 2019, 51, 245.	2.3	44
7	Emergence of colistin resistance in <i>Pseudomonas aeruginosa</i> ST235 clone in South Korea. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 767-769.	2.5	31
8	Colistin Heteroresistance in <i>Klebsiella pneumoniae</i> Isolates and Diverse Mutations of PmrAB and PhoPQ in Resistant Subpopulations. <i>Journal of Clinical Medicine</i> , 2019, 8, 1444.	2.4	31
9	Effect of Early Plasma Exchange on Survival in Patients with Severe Fever with Thrombocytopenia Syndrome: A Multicenter Study. <i>Yonsei Medical Journal</i> , 2017, 58, 867.	2.2	29
10	Comparison of the microbiological characteristics and virulence factors of ST131 and non-ST131 clones among extended-spectrum β -lactamase-producing <i>Escherichia coli</i> causing bacteremia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 102-104.	1.8	26
11	High vancomycin minimum inhibitory concentration is a predictor of mortality in methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 108-113.	2.5	25
12	Rifampicin resistance in <i>Staphylococcus epidermidis</i> : molecular characterisation and fitness cost of rpoB mutations. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 670-677.	2.5	22
13	The ceftazolin inoculum effect in methicillin-susceptible <i>Staphylococcus aureus</i> blood isolates: their association with dysfunctional accessory gene regulator (agr). <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 286-291.	1.8	20
14	High rate of colistin dependence in <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2346-2348.	3.0	20
15	Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β -Lactamase-Producing <i>Escherichia coli</i> Sequence Type 131. <i>Microbial Drug Resistance</i> , 2015, 21, 463-469.	2.0	19
16	Fosfomycin Resistance in <i>Escherichia coli</i> Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics. <i>Antibiotics</i> , 2020, 9, 112.	3.7	19
17	Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β -lactamase-producing <i>Escherichia coli</i> : Potential clinical implications of the revised CLSI interpretive criteria. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 456-459.	2.5	18
18	In Vitro Activities of 21 Antimicrobial Agents Alone and in Combination with Aminoglycosides or Fluoroquinolones against Extended-Spectrum β -Lactamase-Producing <i>Escherichia coli</i> Isolates Causing Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5834-5837.	3.2	17

#	ARTICLE	IF	CITATIONS
19	Variation in formation of persister cells against colistin in <i>Acinetobacter baumannii</i> isolates and its relationship with treatment failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2133-2135.	3.0	17
20	Spontaneous Bacterial Peritonitis due to <i>Ochrobactrum anthropi</i> : A Case Report. <i>Journal of Korean Medical Science</i> , 2007, 22, 377.	2.5	15
21	Dysfunctional accessory gene regulator (<i>agr</i>) as a prognostic factor in invasive <i>Staphylococcus aureus</i> infection: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 20697.	3.3	15
22	Clinical Features of Adult COVID-19 Patients without Risk Factors before and after the Nationwide SARS-CoV-2 B.1.617.2 (Delta)-variant Outbreak in Korea: Experience from Gyeongsangnam-do. <i>Journal of Korean Medical Science</i> , 2021, 36, e341.	2.5	15
23	Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study. <i>Journal of Korean Medical Science</i> , 2022, 37, e134.	2.5	14
24	Predictors of mortality in patients with extensively drug-resistant <i>Acinetobacter baumannii</i> pneumonia receiving colistin therapy. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 175-180.	2.5	12
25	Antimicrobial Effects of β -Lactams on Imipenem-Resistant Ceftazidime-Susceptible <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	12
26	The epidemiology of bloodstream infection contributing to mortality: the difference between community-acquired, healthcare-associated, and hospital-acquired infections. <i>BMC Infectious Diseases</i> , 2022, 22, 336.	2.9	11
27	Response System for and Epidemiological Features of COVID-19 in Gyeongsangnam-do Province in South Korea. <i>Clinical Infectious Diseases</i> , 2021, 72, 661-667.	5.8	10
28	Colistin Resistance and Extensive Genetic Variations in <i>PmrAB</i> and <i>PhoPQ</i> in <i>Klebsiella Pneumoniae</i> Isolates from South Korea. <i>Current Microbiology</i> , 2020, 77, 2307-2311.	2.2	9
29	Clinical Characteristics and Risk Factors for Mortality in Critical Coronavirus Disease 2019 Patients 50 Years of Age or Younger During the Delta Wave: Comparison With Patients \geq 50 Years in Korea. <i>Journal of Korean Medical Science</i> , 2022, 37, .	2.5	9
30	Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers. <i>Vaccines</i> , 2021, 9, 931.	4.4	8
31	Detection of colistin-resistant populations prior to antibiotic exposure in KPC-2-producing <i>Klebsiella pneumoniae</i> clinical isolates. <i>Journal of Microbiology</i> , 2021, 59, 590-597.	2.8	7
32	Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β -lactamase-producing <i>Escherichia coli</i> infections. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 146-157.	1.7	7
33	Two Distinct Genotypes of KPC-2-Producing <i>Klebsiella pneumoniae</i> Isolates from South Korea. <i>Antibiotics</i> , 2021, 10, 911.	3.7	6
34	Residual Lung Lesions at 1-year CT after COVID-19. <i>Radiology</i> , 2022, 302, 720-721.	7.3	6
35	An Outbreak of Breakthrough Infections by the SARS-CoV-2 Delta Variant in a Psychiatric Closed Ward. <i>Journal of Korean Medical Science</i> , 2022, 37, e28.	2.5	5
36	Potassium intake, skeletal muscle mass, and effect modification by sex: data from the 2008-2011 KNHANES. <i>Nutrition Journal</i> , 2020, 19, 93.	3.4	4

#	ARTICLE	IF	CITATIONS
37	Case-Control Study of the Risk Factors for Acquisition of Pseudomonas and Proteus Species during Tigecycline Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5830-5833.	3.2	3
38	Metronidazole therapy as initial treatment of Clostridium difficile infection in patients with chronic kidney disease in Korea. <i>Epidemiology and Infection</i> , 2019, 147, e289.	2.1	3
39	Differences in Clinical Characteristics and Chest Images between Coronavirus Disease 2019 and Influenza-Associated Pneumonia. <i>Diagnostics</i> , 2021, 11, 261.	2.6	2
40	Current Strategy and Perspective View for Preventing Clostridioides Difficile Infection in Acute Care Facilities. <i>Korean Journal of Healthcare-Associated Infection Control and Prevention</i> , 2021, 26, 70-82.	0.6	2
41	Clinical characteristics and the diagnostic role of molecular tests in musculoskeletal infections caused by nontuberculous Mycobacterium: a single-center experience. <i>Infection</i> , 2022, , 1.	4.7	0